Intensive chemotherapy of metastatic colorectal cancer: weighing between safety and clinical efficacy Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial, Evaluation of Lancet Oncol Expert Opin Biol Ther, vol.11, issue.11, pp.845-52821, 2010. ,
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1417, 2009. ,
DOI : 10.1056/NEJMoa0805019
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.27, issue.5, pp.663-671, 2009. ,
DOI : 10.1200/JCO.2008.20.8397
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab, JNCI Journal of the National Cancer Institute, vol.97, issue.13, pp.981-989, 2005. ,
DOI : 10.1093/jnci/dji174
The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-ras Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer, The Oncologist, vol.14, issue.1, pp.22-28, 2009. ,
DOI : 10.1634/theoncologist.2008-0213
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial, The Lancet Oncology, vol.11, issue.1, pp.38-47, 2010. ,
DOI : 10.1016/S1470-2045(09)70330-4
"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study, BMC Cancer, vol.28, issue.13, p.567, 2010. ,
DOI : 10.1016/S0140-6736(00)02528-9
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial, The Lancet Oncology, vol.11, issue.9, pp.845-852, 2010. ,
DOI : 10.1016/S1470-2045(10)70175-3
Cetuximab plus chronomodulated irinotecan, 5-fluorouracil, leucovorin and oxaliplatin as neoadiuvant chemotherapy in colorectal liver metastases ,
Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis, JNCI Journal of the National Cancer Institute, vol.103, issue.1, pp.21-30, 2011. ,
DOI : 10.1093/jnci/djq456
Effectiveness of Liver Metastasectomies in Patients With Metastatic Colorectal Cancer Treated With FIr-B/FOx Triplet Chemotherapy Plus Bevacizumab, Clinical Colorectal Cancer, vol.11, issue.2, pp.119-126, 2012. ,
DOI : 10.1016/j.clcc.2011.11.002
Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice, Clinical Colorectal Cancer, vol.11, issue.4, pp.229-237, 2012. ,
DOI : 10.1016/j.clcc.2012.05.001
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease, BMC Medicine, vol.60, issue.1, p.135, 2012. ,
DOI : 10.1016/S1470-2045(09)70330-4
URL : https://hal.archives-ouvertes.fr/inserm-00764322
COSMIC 2005, British Journal of Cancer, vol.57, issue.2, pp.318-322, 2005. ,
DOI : 10.1126/science.1096096
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study, Br J Cancer, vol.85, pp.692-696, 2001. ,
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC, Nature Reviews Clinical Oncology, vol.276, issue.9, pp.519-527, 2009. ,
DOI : 10.1038/nrclinonc.2009.111
Hyperactive Ras in developmental disorders and cancer, Nature Reviews Cancer, vol.91, issue.4, pp.295-308, 2007. ,
DOI : 10.1038/nrc2109
K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression, Cancer Res, vol.60, pp.6750-6756, 2000. ,
Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia, Nature, vol.12, issue.6022, pp.726-730, 1985. ,
DOI : 10.1038/315726a0
Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" Study, JNCI Journal of the National Cancer Institute, vol.90, issue.9, pp.675-684, 1998. ,
DOI : 10.1093/jnci/90.9.675
Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study, Cancer Epidemiol Biomarkers Prev, vol.9, pp.1193-1197, 2000. ,
Mutation Is More Relevant Than Microsatellite Instability Status for the Prediction of Disease-Free Survival in Adjuvant-Treated Stage III Colon Cancer Patients, Journal of Clinical Oncology, vol.23, issue.24, pp.5635-5643, 2005. ,
DOI : 10.1200/JCO.2005.04.096
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy, British Journal of Cancer, vol.14, issue.8, pp.1166-1169, 2007. ,
DOI : 10.1093/jnci/92.3.205
Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls, Modern Pathology, vol.46, issue.8, pp.1090-1100, 2011. ,
DOI : 10.1038/modpathol.2011.60
New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI: Journal of the National Cancer Institute, vol.92, issue.3, pp.205-216, 2000. ,
DOI : 10.1093/jnci/92.3.205
Nonparametric Estimation from Incomplete Observations, Journal of the American Statistical Association, vol.37, issue.282, pp.457-481, 1958. ,
DOI : 10.1214/aoms/1177731566
Asymptotically Efficient Rank Invariant Test Procedures, Journal of the Royal Statistical Society. Series A (General), vol.135, issue.2, pp.185-206, 1972. ,
DOI : 10.2307/2344317
Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers, Clinical Cancer Research, vol.18, issue.17, pp.4753-4763, 2012. ,
DOI : 10.1158/1078-0432.CCR-11-3210
Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.26, issue.35, pp.5705-5712, 2008. ,
DOI : 10.1200/JCO.2008.18.0786
Mutation Status, Journal of Clinical Oncology, vol.29, issue.15, pp.2011-2019, 2011. ,
DOI : 10.1200/JCO.2010.33.5091
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study, Annals of Oncology, vol.22, issue.7, pp.1535-1546, 2011. ,
DOI : 10.1093/annonc/mdq632
G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab, Journal of Clinical Oncology, vol.30, issue.29, pp.3570-3577, 2012. ,
DOI : 10.1200/JCO.2012.42.2592
Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab, JAMA, vol.304, issue.16, pp.1812-1820, 2010. ,
DOI : 10.1001/jama.2010.1535
p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer, Cancer, vol.5, issue.4, pp.714-721, 2013. ,
DOI : 10.1002/cncr.27804
URL : https://hal.archives-ouvertes.fr/in2p3-00010893
Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis, Cancer Chemotherapy and Pharmacology, vol.2, issue.1, pp.265-272, 2013. ,
DOI : 10.1007/s00280-012-2005-9
Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab, Journal of Clinical Oncology, vol.31, issue.6, pp.759-765, 2013. ,
DOI : 10.1200/JCO.2012.45.1492